BioSpace News Archive

Drug Development

Aura Biosciences Announces Interim Phase Ib/II Data on Light-Activated AU-011 for Primary Ocular Melanoma

Interim data presented today at AAO show that the drug candidate was generally well-tolerated, with no serious adverse events reported, in the first six patients at three to six months post-treatment of AU-011.

November 11, 2017
·
4 min read
ZEISS Unveils Digitalization and Diagnostic Advancements for Eye Care at AAO 2017

During the 2017 AAO Annual Meeting in New Orleans, the Medical Technology business group of ZEISS presents new technologies advancing the digitalization of eye care, including VERACITY Surgical, a cloud-based cataract surgery planning platform which helps surgeons provide personalized technology-enabled patient care and excellent results.

November 11, 2017
·
6 min read
Drug Development

Syndax Pharma Announces Presentation of Data from Immuno-oncology Clinical Trials at the Society for Immunotherapy of Cancer 32nd Annual Scientific Meeting

Syndax Pharma today announced results from the NSCLC and melanoma cohorts of ENCORE 601, an open-label, Phase Ib/II clinical trial employing a Simon two-stage design to evaluate the combination of entinostat plus Merck’s anti-PD-1 therapy, KEYTRUDA.

November 11, 2017
·
8 min read
ZEISS Introduces VERACITY Surgical at AAO 2017

ZEISS announced today the introduction of the US market of VERACITY Surgical, a powerful, intuitive cloud-based platform for cataract surgery planning, logistics, treatment, risk management and analysis.

November 11, 2017
·
4 min read
Drug Development

Nektar Stock Blows Up on Encouraging Data to Treat Difficult Cancers

The initial results were presented at the 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting.

November 11, 2017
·
31 min read
Genetown

Pan-Mass Challenge Announces Record-Shattering $51M Gift to Dana-Farber Cancer Institute

With this gift, the PMC has brought its fundraising total to$598M since its inception in 1980.

November 11, 2017
·
5 min read